79 related articles for article (PubMed ID: 8938186)
21. Influence of phenobarbital on changes in Na(+) handling, hemodynamics and liver function due to partial portal vein ligation in rats.
Sabra R; Shuman S
Eur J Pharmacol; 2001 Feb; 413(2-3):287-94. PubMed ID: 11226405
[TBL] [Abstract][Full Text] [Related]
22. Metabolic fact of 14C-isosorbide 5-mononitrate in humans.
Wood SG; John BA; Chasseaud LF; Major RM; Forrest ME; Bonn R; Darragh A; Lambe RF
Arzneimittelforschung; 1984; 34(9):1031-5. PubMed ID: 6542370
[TBL] [Abstract][Full Text] [Related]
23. Effect of organic nitrates on ex vivo platelet aggregation and fibrinolysis in man.
Wolfram G; Meyer U; Scheske U; Horn M; Drummer C; Spannagl M; Gerzer R
Eur J Med Res; 1996 Mar; 1(6):291-8. PubMed ID: 9367942
[TBL] [Abstract][Full Text] [Related]
24. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Morrison RA; Fung HL
J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969
[TBL] [Abstract][Full Text] [Related]
25. Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.
Lefebvre RA; De Wilde G; Rosseel MT; Duprez D; De Sutter J; Pocchiari F
Eur J Clin Pharmacol; 1992; 42(5):549-52. PubMed ID: 1607003
[TBL] [Abstract][Full Text] [Related]
26. Effect of isosorbide dinitrate on gastric blood flow in rats with liver cirrhosis determined by analyzing gastric blood flow, portal vein pressure and blood gas.
Takiguchi F; Irisawa A; Saito A; Sakamoto H; Obara K; Kasukawa R; Ohira H
Fukushima J Med Sci; 2006 Dec; 52(2):111-24. PubMed ID: 17427762
[TBL] [Abstract][Full Text] [Related]
27. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
Chen YH; Ding PY; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
[TBL] [Abstract][Full Text] [Related]
28. Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.
Sziegoleit W; Dannenberg K; Konschak A; Lautenschläger C; Presek P
Arzneimittelforschung; 2007; 57(2):81-6. PubMed ID: 17396617
[TBL] [Abstract][Full Text] [Related]
29. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of intracerebroventricular insulin microinjection on renal sodium handling and arterial blood pressure in rats.
Menegon LF; Zaparolli A; Boer PA; de Almeida AR; Gontijo JA
Brain Res Bull; 2008 Jul; 76(4):344-8. PubMed ID: 18502308
[TBL] [Abstract][Full Text] [Related]
31. [Changes in the mechanical and electrophysiological properties of isolated blood vessels as a result of isosorbide-5-mononitrate. A comparison with the effect of other organic nitrates].
Biamino G; Nöring J
Med Welt; 1981 Apr; 32(14A):503-7. PubMed ID: 7242309
[No Abstract] [Full Text] [Related]
32. Zea mays L. extracts modify glomerular function and potassium urinary excretion in conscious rats.
Velazquez DV; Xavier HS; Batista JE; de Castro-Chaves C
Phytomedicine; 2005 May; 12(5):363-9. PubMed ID: 15957371
[TBL] [Abstract][Full Text] [Related]
33. Duplex Doppler ultrasonography allows a multiorgan noninvasive approach to splanchnic pharmacodynamics in patients with cirrhosis.
Bolognesi M; Sacerdoti D; Merkel C; Caregaro L; Bellon S; Gatta A
Bildgebung; 1995 Jun; 62(2):138-43. PubMed ID: 7663138
[TBL] [Abstract][Full Text] [Related]
34. Isosorbide 5-mononitrate kinetics.
Major RM; Taylor T; Chasseaud LF; Darragh A; Lambe RF
Clin Pharmacol Ther; 1984 May; 35(5):653-9. PubMed ID: 6713775
[TBL] [Abstract][Full Text] [Related]
35. Influence of spironolactone on urinary prostaglandin E2 and kinin excretion in rats.
Honda M; Hatano M
Prostaglandins Leukot Essent Fatty Acids; 1988 Jan; 31(1):17-21. PubMed ID: 3163804
[TBL] [Abstract][Full Text] [Related]
36. Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic.
McInnes GT; Clarke JM; Shelton JR
Clin Pharmacol Ther; 1983 Jan; 33(1):35-43. PubMed ID: 6848297
[TBL] [Abstract][Full Text] [Related]
37. Spironolactone dose-response relationships in healthy subjects.
McInnes GT; Perkins RM; Shelton JR; Harrison IR
Br J Clin Pharmacol; 1982 Apr; 13(4):513-8. PubMed ID: 7066166
[TBL] [Abstract][Full Text] [Related]
38. [Influence of spironolactone on urinary prostaglandin E2 and kinin excretions in spontaneously hypertensive rats].
Honda M; Izumi Y; Hatano M
Nihon Naibunpi Gakkai Zasshi; 1988 Jan; 64(1):31-8. PubMed ID: 3288509
[TBL] [Abstract][Full Text] [Related]
39. The role of central blood volume in the development of sodium retention in portal hypertensive rats.
Colombato LA; Albillos A; Groszmann RJ
Gastroenterology; 1996 Jan; 110(1):193-8. PubMed ID: 8536856
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate.
Iversen HK; Nielsen TH; Garre K; Tfelt-Hansen P; Olesen J
Eur J Clin Pharmacol; 1992; 42(1):31-5. PubMed ID: 1541314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
